Argus Research Raises Cencora (COR) Price Target to $380

By TradeTexts Research Desk Oct 20, 2026, 11:15 AM EDT

Key Points

Argus Research maintained a Buy rating on Cencora, Inc. on October 20, 2026, lifting its price target to $380 from $340.
Argus Research's $380 price target implies 11.76% upside from Cencora, Inc.'s ($COR) current $340 share price.
Cencora posts trailing twelve month revenue of $332.77 billion alongside an earnings per share of $13.47, with its next earnings report due on November 4, 2026.
Wall Street maintains a consensus buy rating for the medical distributor, backed by 12 analyst opinions.

Get Cencora text alerts

We text you when insiders, Congress, analysts or big funds move on $COR.

By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Cencora, Inc. alert may contain errors. Disclosures

On October 20, 2026, Argus Research kept its Buy rating on Cencora, Inc. (NYSE: COR) while lifting its price target to $380 from $340. Wall Street research firms routinely update their price targets to reflect changing market conditions and company outlooks.

COR Cencora, Inc.

$340 +0.93% year to date

Daily close · Oct 19, 2026

Analyst rating track record

Argus Research vs. the S&P 500

YTD return +7.91% hypothetical

All-time return +7.91% S&P 500 +0.89%

vs. S&P 500 +7.02% ahead of the index

Hypothetical returns from Argus Research's disclosed trades, not real profit or advice. How we model this.

Argus Research's Call on Cencora

On October 20, 2026, Argus Research kept its Buy rating on Cencora and raised its price target to $380 from $340. This follows recent adjustments from other firms, such as UBS maintaining a Buy rating on October 16 with a $400 target.

Other Institutional Activity in Cencora

Fort Washington Investment Advisors grew its holdings by 185,057 shares, ending with 431,763 shares worth about $129,636,841. Boston Partners grew its holdings by 385,970 shares, ending with 4,868,782 shares worth about $1,666,632,754.

Cencora, Inc. Stock Holds Steady

Cencora recently traded around $340.00 on October 20, 2026, while the stock closed that day at $342.31.

12-month forecast

$COR price target

Cencora, Inc. daily closes and this analyst's $380 target. Not advice.

Recent Earnings

For the trailing twelve months, Cencora reported $332,771,328,000 in revenue and earnings per share of $13.47. The company generated a return on equity of 96.9% and a net profit margin of 0.8%. Investors look ahead to the next earnings release scheduled for November 4, 2026.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

F 29/100

Reported May 6, 2026

Forward outlook
4 target cuts vs 0 raises.
EPS & revenue
EPS missed estimates by 2.3%. Revenue missed estimates by 4.3%.
Profit surprise
EBITDA beat by 9 percent. Operating income met by 2 percent.
Pre-earnings setup
Bar was high, analysts already very bullish.
Analyst signal
4 target cuts.
Earnings quality
Gross margin up 0.8 points. Positive free cash flow.

Earnings Call Summary

The company delivered a strong first quarter with 12 percent operating income growth and 9 percent earnings per share growth, driven by continued strength in specialty pharmaceuticals, particularly GLP-1 products which grew 11 percent. Management highlighted that US healthcare solutions performed at the high end of long-term guidance even excluding recent acquisitions like RCA and the newly closed OneOncology deal. The completion of the OneOncology acquisition marks a major strategic expansion of Cencora's managed service organization platform, which management views as a natural extension of its specialty pharmaceutical leadership.

Guidance Cencora raised full year revenue growth guidance to 7 to 9 percent from 5 to 7 percent, and operating income growth to 11.5 to 13.5 percent from 8 to 10 percent. The company closed its OneOncology acquisition and expects the MSO platform to drive meaningful operating income expansion this year and beyond.

Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.

Dividend

Cencora pays an annual dividend rate of $2.40 per share, offering a dividend yield of 0.71% with a payout ratio of 17.4%.

Insider Buying and Selling at Cencora, Inc.

Company insiders have completed several transactions recently. On August 24, 2026, officer Elizabeth S Campbell sold 11,300 shares at $324.12 for a total value of $3,662,663. On September 1, 2026, officer Lazarus Krikorian sold 985 shares at $325.97 for $321,080. On September 16, 2026, director Lon R Greenberg sold 1,280 shares at $321.30 for $411,264. Later, on October 1, 2026, Lazarus Krikorian sold 986 shares at $303.18 for $298,935.

Analysts Set New Price Targets

Analyst coverage includes multiple firms evaluating the medical distributor. RBC Capital initiated coverage on August 19, 2026, with a Sector Perform rating and a $330 price target, then reiterated that stance on September 8. Leerink Partners maintained an Outperform rating on October 7 with a target of $388. UBS maintained a Buy rating on October 16 with a target of $400. Overall, the stock carries a consensus buy recommendation from 12 analyst opinions with a mean price target of $367.67.

About Cencora

Headquartered in Conshohocken, Pennsylvania, Cencora operates in the healthcare sector as a medical distributor, sourcing and distributing pharmaceutical products globally. The company employs 47,000 people and is led by CEO Dr. Robert P. Mauch.

Bottom Line

Argus Research's target increase brings added attention to Cencora ahead of its upcoming earnings release. Market participants will watch for further updates on financial performance when the company reports results on November 4, 2026.